“Arimidex Direct” Program Will Provide Branded Cancer Drug To U.S. Patients For $40 A Month
This article was originally published in The Pink Sheet Daily
Executive Summary
Spurred on by patient requests for affordable access to the branded version of now generic anastrozole, AstraZeneca will partner with Express Scripts to provide the drug direct to patients at a fixed co-payment.
You may also be interested in...
AstraZeneca Hit By U.S. Generic Competition In 2010; Extends Share Buyback Program
Revenues flat year on year, but profits up 5% in a year of cost savings and late-stage product disappointments.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.